CIPLA | AJANTA PHARMA | CIPLA/ AJANTA PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 36.9 | 27.7 | 133.1% | View Chart |
P/BV | x | 4.3 | 6.8 | 62.5% | View Chart |
Dividend Yield | % | 0.5 | 0.5 | 92.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
AJANTA PHARMA Mar-19 |
CIPLA/ AJANTA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 1,422 | 41.2% | |
Low | Rs | 357 | 898 | 39.8% | |
Sales per share (Unadj.) | Rs | 207.0 | 233.5 | 88.7% | |
Earnings per share (Unadj.) | Rs | 18.6 | 44.0 | 42.3% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 52.2 | 63.6% | |
Dividends per share (Unadj.) | Rs | 4.00 | 9.00 | 44.4% | |
Dividend yield (eoy) | % | 0.8 | 0.8 | 109.4% | |
Book value per share (Unadj.) | Rs | 195.5 | 255.1 | 76.6% | |
Shares outstanding (eoy) | m | 806.35 | 88.02 | 916.1% | |
Bonus/Rights/Conversions | ESOS | BB | - | ||
Price / Sales ratio | x | 2.3 | 5.0 | 45.8% | |
Avg P/E ratio | x | 25.3 | 26.4 | 96.0% | |
P/CF ratio (eoy) | x | 14.2 | 22.2 | 63.9% | |
Price / Book Value ratio | x | 2.4 | 4.5 | 53.0% | |
Dividend payout | % | 21.5 | 20.5 | 105.1% | |
Avg Mkt Cap | Rs m | 379,912 | 102,081 | 372.2% | |
No. of employees | `000 | 25.8 | 6.8 | 380.1% | |
Total wages/salary | Rs m | 30,270 | 4,307 | 702.8% | |
Avg. sales/employee | Rs Th | 6,459.6 | 3,022.6 | 213.7% | |
Avg. wages/employee | Rs Th | 1,171.2 | 633.4 | 184.9% | |
Avg. net profit/employee | Rs Th | 580.2 | 569.1 | 102.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 20,554 | 812.3% | |
Other income | Rs m | 3,442 | 211 | 1,632.8% | |
Total revenues | Rs m | 170,391 | 20,765 | 820.6% | |
Gross profit | Rs m | 32,060 | 5,664 | 566.0% | |
Depreciation | Rs m | 11,747 | 721 | 1,629.6% | |
Interest | Rs m | 1,974 | 12 | 17,013.8% | |
Profit before tax | Rs m | 21,782 | 5,143 | 423.5% | |
Minority Interest | Rs m | -475 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,312 | 1,273 | 495.8% | |
Profit after tax | Rs m | 14,995 | 3,870 | 387.5% | |
Gross profit margin | % | 19.2 | 27.6 | 69.7% | |
Effective tax rate | % | 29.0 | 24.8 | 117.1% | |
Net profit margin | % | 9.0 | 18.8 | 47.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 11,812 | 990.8% | |
Current liabilities | Rs m | 43,931 | 3,776 | 1,163.3% | |
Net working cap to sales | % | 43.8 | 39.1 | 112.0% | |
Current ratio | x | 2.7 | 3.1 | 85.2% | |
Inventory Days | Days | 96 | 77 | 123.7% | |
Debtors Days | Days | 85 | 82 | 104.3% | |
Net fixed assets | Rs m | 107,424 | 14,398 | 746.1% | |
Share capital | Rs m | 1,613 | 175 | 919.3% | |
"Free" reserves | Rs m | 156,018 | 22,277 | 700.4% | |
Net worth | Rs m | 157,630 | 22,452 | 702.1% | |
Long term debt | Rs m | 23,693 | 7 | 358,981.8% | |
Total assets | Rs m | 236,626 | 26,962 | 877.6% | |
Interest coverage | x | 12.0 | 444.3 | 2.7% | |
Debt to equity ratio | x | 0.2 | 0 | 51,131.7% | |
Sales to assets ratio | x | 0.7 | 0.8 | 92.6% | |
Return on assets | % | 7.2 | 14.4 | 49.8% | |
Return on equity | % | 9.5 | 17.2 | 55.2% | |
Return on capital | % | 12.8 | 23.0 | 55.9% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 10,682 | 524.6% | |
Fx outflow | Rs m | 6,764 | 2,102 | 321.8% | |
Net fx | Rs m | 49,272 | 8,580 | 574.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 3,748 | 818.7% | |
From Investments | Rs m | 1,040 | -2,228 | -46.7% | |
From Financial Activity | Rs m | -29,488 | -1,475 | 1,999.7% | |
Net Cashflow | Rs m | 2,340 | 45 | 5,177.4% |
Indian Promoters | % | 16.0 | 73.8 | 21.7% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 1.6 | 787.1% | |
FIIs | % | 23.7 | 7.6 | 311.8% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 17.0 | 154.1% | |
Shareholders | 161,166 | 20,968 | 768.6% | ||
Pledged promoter(s) holding | % | 0.0 | 4.4 | - |
Compare CIPLA With: IPCA LABS PANACEA BIOTECH FDC TORRENT PHARMA FRESENIUS KABI ONCO.
Compare CIPLA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
CIPLA share price is trading up by 5% and its current market price is Rs 850. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are CIPLA (up 5.0%) and AUROBINDO PHARMA (up 9.6%). The top losers are NATCO PHARMA (down 0.2%) and PIRAMAL ENTERPRISES (down 0.6%).
For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More